Article PDF
Avoid common mistakes on your manuscript.
References
Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017; 140: 645–53.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62.
Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 2018; 201: 1605–13.
Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad of Dermatol 2020; 82: 1217–8.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. J Am Acad of Dermatol. Ahead of print. doi:https://doi.org/10.1016/j.jaad.2020.04.085.
Tian Y, Jiang C, Wang M, et al. BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000–14. Lancet Diabetes Endocrinol 2016; 4: 487–97.
Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019; 155: 1142–52.
Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Saf 2016; 15: 11–34.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Acknowledgments and disclosures
Funding: this work was supported by HUST COVID-19 Rapid Response Call Program (2020kfyXGYJ056) and Hubei Provincial Emergency Science and Technology Program for COVID-19 (2020FCA037). Conflicts of interest: none. Acknowledgments: we would like to thank all research stafffor their support in this study. The patients in this manuscript have provided informed consent for the publication of their case details.
About this article
Cite this article
Zhao, L., Du, H., Alamgir, M. et al. Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China. Eur J Dermatol 30, 738–740 (2020). https://doi.org/10.1684/ejd.2020.3908
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2020.3908